冠状动脉内膜剥脱术联合冠状动脉旁路移植术患者桥接双联抗血小板治疗中替罗非班与肝素的早期比较:多中心随机对照试验方案(THACE-CABG试验)
针对弥漫性冠状动脉疾病需行冠状动脉内膜剥脱联合冠状动脉旁路移植术(CE-CABG)的患者,术后高危期桥接双联抗血小板治疗(DAPT)方案尚不统一。本试验第一阶段将266例患者随机分配至替罗非班组与肝素组,比较主要安全终点即术后24小时胸管引流量;若替罗非班显示非劣效,第二阶段将再随机分配464例,共730例患者比较术后30天主要心脑血管不良事件(MACCE)。
要点
- CE-CABG术后高危期桥接DAPT方案尚无统一标准,本试验比较替罗非班与肝素的安全性和有效性。
- 第一阶段主要安全终点为术后24小时胸管引流量,共纳入266例患者随机分组。
- 若第一阶段显示替罗非班非劣效,第二阶段再纳入464例,共730例比较术后30天MACCE。
核心结论
- 本试验旨在比较替罗非班与肝素作为CE-CABG术后DAPT桥接策略的安全性和有效性。
- 鉴于CE-CABG术后给予替罗非班可能带来的获益,本试验有潜力推动成人冠状动脉心脏外科领域的发展。
研究设计与样本
- 多中心随机对照试验方案,分两阶段进行。
- 第一阶段纳入266例接受CE-CABG的患者,随机分配至替罗非班组与肝素组,比较主要安全终点即术后24小时胸管引流量。
- 若第一阶段显示替罗非班非劣效,则启动第二阶段,再随机分配464例患者,全部730例患者用于比较术后30天MACCE。
关键数值与推荐
- 第一阶段主要安全终点为术后24小时胸管引流量。
- 第二阶段主要终点为术后30天主要心脑血管不良事件(MACCE)。
- 第一阶段样本量为266例,第二阶段新增464例,总样本量为730例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For complete revascularization, patients with diffuse coronary artery disease should have a coronary endarterectomy and a coronary artery bypass graft (CE-CABG). Sadly, CE can lead to a lack of endothelium, which raises the risk of thrombotic events. Even though daily dual antiplatelet therapies (DAPT) have been shown to reduce thrombotic events, the risk of perioperative thrombotic events is high during the high-risk period after CE-CABG, and there is no consistent protocol to bridge DAPT. This trial aims to compare safety and efficacy between tirofiban and heparin as DAPT bridging strategies after CE-CABG. METHODS: In phase I, 266 patients undergoing CE-CABG will be randomly assigned to tirofiban and heparin treatment groups to compare the two treatments in terms of the primary safety endpoint, chest tube drainage in the first 24 h. If the phase I trial shows tirofiban non-inferiority, phase II will commence, in which an additional 464 patients will be randomly assigned. All 730 patients will be studied to compare major cardiovascular and cerebrovascular events (MACCEs) between the groups in the first 30 days after surgery. DISCUSSION: Given the possible benefits of tirofiban administration after CE-CABG, this trial has the potential to advance the field of adult coronary heart surgery. TRIAL REGISTRATION: chictr.org.cn, ChiCTR2200055697. Registered 6 January 2022. https://www.chictr.org.cn/com/25/showproj.aspx?proj=149451 . Current version: 20,220,620.
引用
- Chen L, Gao MX, Du X, et al. Early tirofiban versus heparin for bridging dual antiplatelet therapy in patients undergoing coronary endarterectomy combined with coronary artery bypass grafting: a multicenter randomized controlled trial protocol (the THACE-CABG trial). Trials. 2024. PMID: 38225640. doi:10.1186/s13063-023-07737-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。